Journal List > J Korean Ophthalmol Soc > v.51(6) > 1008831

Han, Moon, Kim, Lee, and Lee: Intraindividual Comparison of ICL and Toric ICL Implantation in the Correction of High Myopia With Astigmatism

Abstract

Purpose

We compared intra-individual visual outcomes and patient satisfaction after implantable contact lens (ICL) and Toric ICL implantation.

Methods

Twenty-eight eyes of 14 patients were enrolled in this retrospective study. One eye of each patient was assigned to ICL (ICL Group), and the contralateral eye was allocated to Toric ICL (Toric ICL Group). All patients were examined for visual acuity, refraction, intraocular pressure, slit lamp measurements, and satisfaction one week, one month, two months, and six months postoperatively.

Results

Mean spherical equivalents of the two groups were corrected from -7.83D (ICL Group) and -5.55D (Toric ICL Group) to 0.13D and 0.20D, respectively, and the mean refractive cylinders were corrected from 0.92D and 2.60D to 0.42D and 0.27D, respectively, at six months postoperatively. The myopias of these two groups and the astigmatism of the Toric ICL group were effectively corrected. The uncorrected visual acuity (UCVA) of the two groups were 1.02 and 1.05, respectively, at six months postoperatively. The safety index, efficacy index, predictability, and stability were favorable. There were no significant differences between the two groups in terms of postoperative UCVA, intraocular pressure(IOP), vaulting, noticeable complications, or patient satisfaction.

Conclusions

The results show ICL implantation is effective treatment for high myopia, and Toric ICL implantation is a viable surgical option for the treatment of compound myopia astigmatism. Selection of proper phakic intraocular lens(IOL) is recommended for correcting astigmatism.

References

1. Lovisolo CF, Reinstein DZ. Phakic intraocular lenses. Surv Ophthalmol. 2005; 50:549–87.
crossref
2. Maloney RK, Nguyen LH, John ME. Artisan phakic intraocular lens for myopia:short-term results of a prospective, multicenter study. Ophthalmology. 2002; 109:1631–41.
3. Stulting RD, John ME, Maloney RK, et al. Three-year results of Artisan/Verisyse phakic intraocular lens implantation. Results of the United States Food And Drug Administration clinical trial. Ophthalmology. 2008; 115:464–72.
4. Bartels MC, Saxena R, van den Berg TJ, et al. The influence of incision-induced astigmatism and axial lens position on the correction of myopic astigmatism with the Artisan toric phakic intraocular lens. Ophthalmology. 2006; 113:1110–7.
crossref
5. Coullet J, Guell JL, Fournie P, et al. Iris-supported phakic lenses (rigid vs foldable version) for treating moderately high myopia: randomized paired eye comparison. Am J Ophthalmol. 2006; 142:909–16.
crossref
6. Chun YS, Lee JH, Lee JM, et al. Outcomes after implantable contact lens for moderate to high myopia. J Korean Ophthalmol Soc. 2004; 45:480–9.
7. Han SY, Lee KH. Long term effect of ICL implantation to treat high myopia. J Korean Ophthalmol Soc. 2007; 48:465–72.
8. Sanders DR, Brown DC, Martin RG, et al. Implantable contact lens for moderate to high myopia: phase I FDA clinical study with 6 month followup. J Cataract Refract Surg. 1998; 24:607–11.
9. Sanders DR, Vukich JA, Doney K, Gaston M. U.S. Food and Drug administration clinical trial of the implantable contact lens for moderate to high myopia. Ophthalmology. 2003; 110:255–66.
crossref
10. Sanders DR, Schneider D, Martin R, et al. Toric Implantable Collamer Lens for moderate to high myopic astigmatism. Ophthalmology. 2007; 114:54–61.
crossref
11. Uusitalo RJ, Aine E, Sen NH, Laatikainen L. Implantable contact lens for high myopia. J Cataract Refract Surg. 2002; 28:29–36.
crossref
12. Assetto V, Benedetti S, Pesando P. Collamer intraocular contact lens to correct high myopia. J Cataract Refract Surg. 1996; 22:551–6.
crossref
13. Arne JL, Lesueur LC. Phakic posterior chamber lenses for high myopia: functional and anatomical outcomes. J Cataract Refract Surg. 2000; 26:369–74.
crossref
14. Yoon JM, Moon SJ, Lee KH. Clinical Outcomes of Toric Implantable Collamer Lens implantation. J Korean Ophthalmol Soc. 2009; 50:839–51.
crossref
15. Chang J, Lau S. Toric Implantable Collamer Lens for high myopic astigmatic Asian eyes. Ophthalmology. 2009; 116:2340–7.
crossref
16. Jimenez-Alfaro I, Benitez del Castillo JM, Garcia-Feijoo J, et al. Safety of posterior chamber phakic intraocular lenses for the correction of high myopia. Anterior segment changes after posterior chamber phakic intraocular lens implantation. Ophthalmology. 2001; 108:90–9.
17. Mendicute J, Irigoyen C, Ruiz M, et al. Toric intraocular lens versus op-posite clear corneal incisions to correct astigmatism in eyes having cataract surgery. J Cataract Refract Surg. 2009; 35:451–8.
crossref
18. Kamiya K, Shimizu K, Igarashi A, Komatsu M. Comparison of Collamer toric implantable contact lens implantation and wave-front-guided laser in situ keratomileusis for high myopic astigmatism. J Cataract Refract Surg. 2008; 34:1687–93.
19. Sanders DR, Vukich JA. Comparison of implantable contact lens and laser assisted in situ keratomileusis for moderate to high myopia. Cornea. 2003; 22:324–31.
crossref
20. Sanders D, Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for low myopia. Cornea. 2006; 25:1139–46.
crossref
21. Sanders DR, Vukich JA. Incidence of lens opacities and clinically significant cataracts with the implantable contact lens: comparison of two lens designs. J Refract Surg. 2002; 18:673–82.
crossref
22. Gonvers M, Bornet C, Othenin-Girard P. Implantable contact lens for moderate to high myopia: relationship of vaulting to cataract formation. J Cataract Refract Surg. 2003; 29:918–24.
23. Lackner B, Pieh S, Schmidinger G, et al. Long-term results of implantation of phakic posterior chamber intraocular lenses. J Cataract Refract Surg. 2004; 30:2269–76.
crossref
24. Sarikkola A-U, Sen HN, Uusitalo RJ, Laatikainen L. Traumatic cataract and other adverse events with the implantable contact lens. J Cataract Refract Surg. 2005; 31:511–24.
crossref
25. Lege BA, Haigis W, Neuhann TF, Bauer MH. Age-related behavior of posterior chamber lenses in myopic phakic eyes during accommodation measured by anterior segment partial coherence interferometry. J Cataract Refract Surg. 2006; 32:999–1006.
crossref
26. Schallhorn S, Tanzer D, Sanders DR, Sanders ML. Randomized prospective comparison of Visian Toric Implantable Collamer Lens and conventional photorefractive keratectomy for moderate to high myopic astigmatism. J Refract Surg. 2007; 23:853–67.
crossref

Figure 1.
Attempted vs achieved spherical equivalent at 6 months after ICL and Toric ICL implantation.
jkos-51-802f1.tif
Figure 2.
Patient satisfaction of ICL and Toric ICL.
jkos-51-802f2.tif
Table 1.
Patient demographics
lens ICL (14 eyes) Toric ICL (14 eyes) P-value
Age (years) 30.07±8.54
Sex (M : F) 4 : 10
Follow-up duration (Month) 9.8±1.97 (6∼12)
SE (Diopter) -8.30±3.23 -6.85±2.49 0.31
Cyl (Diopter) 0.92±0.34 2.60±1.16 <0.01
BCVApreop (logMAR) 0.90 (0.07) 0.95 (-0.02) 0.89
Table 2.
Comparison of spherical equivalent (SE) over time between the ICL and Toric ICL groups (Diopter)
ICL Toric-ICL P-value
Baseline SE -8.30±3.23 -6.85±2.49 0.31
Postop 1 wk SE 0.29±0.15 0.35±0.40 0.94
Postop 1 Mo SE 0.16±0.23 0.35±0.35 0.22
Postop 2 Mo SE 0.13±0.25 0.31±0.46 0.33
Postop 6 Mo SE 0.13±0.25 0.20±0.16 0.47
Table 3.
Comparison of refractive cylinder (RC) over time between the ICL and Toric ICL groups (Diopter)
ICL Toric ICL P-value
Baseline RC 0.92±0.34 2.60±1.16 <0.01
Postop 1 wk RC 0.51±0.25 0.39±0.35 0.94
Postop 1 Mo RC 0.46±0.20 0.21±0.34 0.22
Postop 2 Mo RC 0.38±0.25 0.25±0.27 0.33
Postop 6 Mo RC 0.42±0.25 0.27±0.25 0.59
Postop 6 Mo RC ≤ ±0.5D 12/14 eyes (85.7%) 13/14 eyes (92.9%)
Table 4.
Preoperative best spectacle-corrected visual acuity (BSCVA), postoperative uncorrected visual acuity (UCVA), safety index and efficacy index at 6 month postoperatively
ICL Toric-ICL P-value
Baseline BSCVA (logMAR) 0.90 (0.07) 0.95 (0.02) 0.89
Postop 1 wk UCVA 1.00 (0.00) 0.99 (0.01) 0.70
Postop 1 Mo UCVA 1.00 (0.00) 0.98 (0.11) 0.79
Postop 2 Mo UCVA 1.01 (0.00) 1.08 (-0.03) 0.82
Postop 6 Mo UCVA 1.02 (0.00) 1.05 (-0.02) 0.80
Safety index 1.21±0.47 1.13±0.21 0.84
Efficacy index 1.25±0.48 1.12±0.21 0.98
Baseline BSCVA ≤ Post 6 Mo UCVA 13/14 (92.9%) 12/14 (85.7%)
TOOLS
Similar articles